Understanding Needs of Older Patients Prior to Starting Cancer Treatment

This study aims to understand how to best provide practical geriatric assessments (PGAs) to older adults starting cancer treatment. A PGA is a way to check an older person's overall health, including physical abilities and support systems, to help improve their cancer care and reduce side effects. Even though PGAs are recommended, they are not often used. This study will gather feedback from oncology clinicians through surveys and interviews to improve how PGAs are delivered. The study will also assess how acceptable these new ways of delivering PGAs are to clinics. This study is for oncology clinicians, not patients, and is currently unclear regarding its status.

Study design: This interventional study plans to enroll 216 participants. It is not specified if it is randomized or blinded.
What's involved: Participants will complete an interest survey and stakeholder interview. They will also receive provider education and written or electronic materials.
Compensation: Not stated in the trial record.
Follow-up: Qualitative feedback will be measured up to 6 months after Part 1 starts. Acceptability of strategies will be measured 6 months after Part 2 starts.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Understanding Needs of Older Patients Prior to Starting Cancer Treatment

Enrolling by Invitation

NAAges 18+InterventionalHealth services

Wake Forest University Health Sciences

~216 participants

Updated 2026-04-08 on ClinicalTrials.gov

What's tested:Survey AdministrationInterviewEducational InterventionAssessmentInternet-Based InterventionElectronic Health Record Review

At a glance

Recruiting sites

0 of 27 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Qualitative feedback on the practical geriatric assessment (PGA) implementation strategies within the context of the National Cancer Institute Community Oncology Research Program (Part 1)

Measured over Up to 6 months after the start of Part 1

+1 more outcome measured

Conditions

Hematopoietic and Lymphatic System Neoplasm

Malignant Solid Neoplasm

NCT07225920

Where you'd take part

This study runs at 27 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Baptist Cancer Center-Grenada
Grenada, Mississippino site contact published
Baptist Memorial Hospital and Cancer Center-Collierville
Collierville, Tennesseeno site contact published
Baptist Memorial Hospital and Cancer Center-Desoto
Southaven, Mississippino site contact published
Baptist Memorial Hospital and Cancer Center-Golden Triangle
Columbus, Mississippino site contact published
Baptist Memorial Hospital and Cancer Center-Memphis
Memphis, Tennesseeno site contact published
Baptist Memorial Hospital and Cancer Center-Oxford
Oxford, Mississippino site contact published
Baptist Memorial Hospital and Cancer Center-Union County
New Albany, Mississippino site contact published
Baptist Memorial Hospital for Women
Memphis, Tennesseeno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

Kathryn Weaver, PhD · STUDY_CHAIR · Wake Forest University Health Sciences

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

PART 1 ONCOLOGY CLINICIANS: Must be an oncology clinician (MDs, DOs, APPs (e.g. NP, PA)) who administers systemic therapy (chemotherapy, immunotherapy or targeted therapy).

PART 1 ONCOLOGY CLINICIANS: Must be involved in the planning or delivery of new systemic therapies (e.g. chemotherapy, immunotherapy, targeted therapy) to patients including those \>= 65 years old

PART 1 ONCOLOGY CLINICIANS: Must be willing to participate in a semi-structured interview (approximately 60 minutes; remotely over the internet or by phone)

PART 1 ONCOLOGY CLINICIANS: Concurrent participation in URCC-19170 is allowed, not required

PART 1 ONCOLOGY CLINICIANS: Must be able to read, understand and speak English

PART 1 ONCOLOGY SUPPORT STAFF STAKEHOLDER: Nurse, practice manager, or other oncology support staff who work with oncology clinicians who provide systemic therapy, help with office workflows for patient screeners, or help patients with referrals (including patients age 65 or older). May include staff that have a dual role in research and clinical support

PART 1 ONCOLOGY SUPPORT STAFF STAKEHOLDER: Must be willing to participate in a semi-structured interview (approximately 60 minutes; remotely over the internet or by phone)

PART 1 ONCOLOGY SUPPORT STAFF STAKEHOLDER: Concurrent participation in URCC-19170 is allowed, not required

PART 1 ONCOLOGY SUPPORT STAFF STAKEHOLDER: Must be able to read, understand and speak English

PART 1 PATIENT STAKEHOLDER: \>= 65 years of age

PART 1 PATIENT STAKEHOLDER: Must have initiated a new line of chemo-/immuno- and/or targeted therapy in the last 12 months

PART 1 PATIENT STAKEHOLDER: Must be willing to participate in a semi-structured interview (approximately 60 minutes; or remotely over the internet or by phone)

PART 1 PATIENT STAKEHOLDER: Concurrent participation in URCC-19170 is allowed, not required

PART 1 PATIENT STAKEHOLDER: Must be able to understand and speak English

PART 1 CAREGIVER STAKEHOLDER: Must self-report as having cared for a patient 65 years or older who initiated systemic treatment (e.g. chemo-, immuno- and/or targeted therapy) in the last 12 months. To allow for differences in how the term "caregiver" is used, we will include any family member, significant other, or friend who helps during their cancer treatment, regardless of whether they define themselves as a caregiver

PART 1 CAREGIVER STAKEHOLDER: Must be willing to participate in a semi-structured interview (approximately 60 minutes; remotely over the internet or by phone)

PART 1 CAREGIVER STAKEHOLDER: Concurrent participation in URCC-19170 is allowed, not required

PART 1 CAREGIVER STAKEHOLDER: Must be able to understand and speak English

PART 2 PRACTICE: Must be an National Cancer Institute Community Oncology Research Program (NCORP) practice (defined as one or more NCORP affiliates/sub-affiliates, which have a common administrative structure and share providers and/or patients)

PART 2 PRACTICE: Must provide outpatient oncology care to at least 50 new patients aged 65 or over starting a new non-hormonal systemic therapy in the past 6 months

PART 2 PRACTICE: Must have received an Introductory Email with a Practice Identification (ID) to be used to enroll the selected affiliate/sub-affiliates in Oncology Patient Enrollment Network (OPEN)

PART 2 PRACTICE: Concurrent participation in URCC-19170 is allowed, not required

PART 2 CLINIC CHAMPION: Must be employed in one of the selected clinics participating in the Part 2 Pilot Study

PART 2 CLINIC CHAMPION: Must not be planning to leave their position in the next 9 months

PART 2 CLINIC CHAMPION: Must provide care for or interact with patients age 65+ or provide administrative leadership over one of the selected clinics participating in the Part 2 Pilot Study

PART 2 CLINIC CHAMPION: Must be willing to lead efforts to support PGA implementation within their clinic

PART 2 CLINIC CHAMPION: Must be willing to complete the 15-minute Initial Clinic Survey at the beginning of the Part 2 Pilot Study

PART 2 CLINIC CHAMPION: Must be willing to participate in the Initial Clinic Visit (in-person \[preferred\] or virtual) with the Medstar Health Research Institute (MHRI) Study Team for an estimated 60-minute in-depth discussion of the protocol. While the champion may not choose to stay with the MHRI Study Team for the rest of the half-day visit, they will facilitate plans for the other parts of the half-day site visit

PART 2 CLINIC CHAMPION: Must be willing to participate in four 30-minute (approximately \[approx.\]) virtual meetings monthly during the pilot study

PART 2 CLINIC CHAMPION: Must be willing to disseminate study materials to other relevant clinical team members, where appropriate invite the MHRI Study Team to present to other relevant clinical team members, and share updates with the MHRI Study Team during monthly virtual meetings

PART 2 CLINIC CHAMPION: Must be willing to oversee the selection of participants to have an EHR review

PART 2 CLINIC CHAMPION: Must be willing to participate in a 45-minute (approx.) virtual, recorded meeting at the end of the Part 2 Pilot Study (or if unavailable to attend the meeting, must be willing to complete a survey) to provide feedback on implementation strategies and on usefulness and acceptability of implementation strategies

PART 2 CLINIC CHAMPION: Concurrent participation in URCC-19170 is allowed, not required

PART 2 CLINIC CHAMPION: Must be able to read, understand and speak English

PART 2 PATIENT: Must be \>= 65 years of age

PART 2 PATIENT: Must have a start date to begin a new line of cancer non-hormonal systemic therapy (i.e., chemotherapy, immunotherapy, and/or targeted therapy). The start date will be captured at OPEN enrollment

PART 2 PATIENT: Must be willing to complete a one-time 15-minute survey

PART 2 PATIENT: Must have completed at least one component of PGA prior to the new non-hormonal systemic therapy initiation, as identified by the local clinic provider or staff

PART 2 PATIENT: Concurrent participation in URCC-19170 is allowed, not required

PART 2 PATIENT: Must be able to understand and speak English

PART 2 CLINIC DEBRIEF MEETING/SURVEY PARTICIPANTS (NOT ALREADY ENROLLED): Must work in or with the clinic that participated in Part 2 Pilot Study

PART 2 CLINIC DEBRIEF MEETING/SURVEY PARTICIPANTS (NOT ALREADY ENROLLED): Concurrent participation in URCC-19170 is allowed, not required

PART 2 CLINIC DEBRIEF MEETING/SURVEY PARTICIPANTS (NOT ALREADY ENROLLED): Must be able to read, understand and speak English

What this trial measures

Qualitative feedback on the practical geriatric assessment (PGA) implementation strategies within the context of the National Cancer Institute Community Oncology Research Program (Part 1)Up to 6 months after the start of Part 1
Thematic analysis will be used to identify suggested modifications that could be used to optimize acceptability of PGA implementation strategies. Intervention materials and implementation strategies will then be refined based on this feedback for further evaluation in the Part 2 Pilot Study.
Acceptability of PGA implementation strategies (Part 2)6 months after the start of Part 2
Acceptability of PGA implementation strategies will be assessed qualitatively during the clinic debrief meeting for those able to attend the meeting. If a participant is unable to attend the meeting, acceptability will instead be assessed quantitatively using the Acceptability of Intervention Measure (AIM) via a REDCap survey. In this case, acceptability will be defined as a score of at least 4 on the AIM. Overall, PGA implementation strategies will be considered acceptable if the majority of participants at the debrief meeting for each clinic agree that the strategies are acceptable. If this metric is not met, strategies will be further refined before the start of the future randomized trial.

Trialytics